Two OncoDaily Mentors, One Global Mission: Matti Aapro and Hesham Elghazaly Run for UICC Board
Pope Leo XIV Lung Cancer Diagnosis: Surgery, Prognosis and Survival Rates
OncoDaily Academy Introduces the First Module of its Six-part Programme on Immune Checkpoint Inhibitors
TRACE-I: Long-Term Outcomes of PSMA-Guided Salvage Surgery in Recurrent Prostate Cancer
Can Distant Lymph Nodes Sustain Immunotherapy After Lymph-Node Surgery?
Melvin L.K. Chua: Defining Where Proton Beam Therapy Benefits Nasopharyngeal Carcinoma
Can Maintenance HER2 Therapy Be Stopped? Global Survey Reveals Clinical Equipoise in Long-Term Responders
Miriam Mutebi: What Does Resilience Really Mean for Women Navigating Our Healthcare Systems?
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
